Glaukos Corp（GKOS）今日盘后股价大涨9.77%，引发市场广泛关注。
消息面上，公司于盘后发布了第二季度财报，数据显示销售额达到1.856亿美元，显著高于市场普遍预期的1.509亿美元，成为推动盘后股价飙升的核心催化剂。尽管公司本季度录得净亏损1840万美元，但营收端的强劲表现极大地提振了投资者信心。
此外，公司近日宣布Preserflo™微型引流器510(k)关键性研究已完成全部患者入组，目标入组至少110名患者，该产品用于治疗既往药物及手术治疗失败的原发性开角型青光眼成人患者，标志着其美国上市进程迈出关键一步。机构方面，Truist将目标价从160美元上调至180美元并维持买入评级，Needham亦多次上调目标价，整体市场情绪偏多。管线里程碑与财报超预期形成共振，共同推动盘后股价大幅走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.